IDH.L Regulatory News (IDH)

26 Sep 2005 07:01

Immunodiagnostic Systems Hldgs PLC26 September 2005 For Immediate Release 26 September 2005 Immunodiagnostic Systems Holdings PLC ("IDS" or the "Company") Board Appointment IDS, a leading producer of diagnostic testing kits, announces the appointment ofDr. Phillip D.K. Lee as Chief Scientific Officer of the company with immediateeffect Dr. Lee, aged 49, received his medical degree from Northwestern UniversityMedical School, Chicago, and held the positions of Assistant Professor ofPaediatrics in Denver (1986-89), and Houston (1989-93), before moving into thecommercial In Vitro Diagnostics environment. In 1993, he joined Diagnostic Systems Laboratories Inc (DSL) of Webster, Texas,as Director of Research & Scientific Affairs. During his tenure at DSL aprodigious range of products, primarily in the area of Insulin-like GrowthFactors (IGF's) and related biomarkers, were launched to an appreciativeresearch and clinical market. In 1998 he returned to research, teaching and clinical practice as Director ofEndocrinology & Metabolism at the Children's Hospital of Orange County,California. In 2002, Dr. Lee moved to the David Geffen School of Medicine atUCLA, where he was appointment Professor of Paediatrics and Clinical Director ofPaediatric Endocrinology at Mattel Children's Hospital at UCLA. The opportunity to re-enter the world of commercial IVD innovation anddevelopment at IDS has brought Dr. Lee to the North East of England, where helooks forward to a highly productive career in a forward-looking company. Dr. Lee commented: "The creative environment in Britain, and particularly atIDS, together with the ability to network with my colleagues and other companiesworldwide, provides an exciting opportunity for the introduction of newtechnologies and new products. I'm looking forward to the future challenges andsuccesses we will experience". Managing Director IDS, Dr Roger Duggan, said: 'We are delighted to haveattracted a scientist of Phil's calibre to drive our push into new demandingareas of technology, and to achieve the accelerated biomarker discovery andproduct delivery that will ensue. Phil also has plans to participate in someteaching, research and clinically-related activities within Newcastle UniversityMedical School, who welcome input from such an eminent and well-publishedclinical practitioner". Save as set out below, there is no further information to disclose in respect ofDr Lee under paragraph (f) of schedule 2 to the AIM rules. Previous Directorships: Children's Hospital of Orange County; Director of Endocrinology, 1998-2002David Geffen School of Medicine at UCLA, Clinical Director of PediatricEndocrinology; 2002-2005 Enquiries: IDS Holdings plc Binns & Co PR Ltd David Evans, Chairman Roger Duggan, Managing Director Paul McManusTel: 07740 084 452 Tel: 0191 519 6109 Tel: 020 7153 1485 Mob: 07980 541 893 This information is provided by RNS The company news service from the London Stock Exchange